SavedAdd your journal

Journals / Southern Clinics of Istanbul Eurasia / 2020 / Cilt: 31 - Sayı: 4

Incidence of Metabolic Syndrome in Anti-Hepatitis C Virus Positive Patients

Sevtap ŞENOĞLU
Arzu Cennet IŞIK
Ramazan KORKUSUZ
Hayriye Esra ATAOĞLU
Mehmet Emirhan IŞIK
Semra ÖZGÜMÜŞ
Pages
370–375
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In our study, the prevalence of MS was significantly higher in female patients with HCV antibodies than in male patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Research has shown that hepatitis C infection, metabolic syndrome (MS), and non-alcoholic fatty liver syndrome are associated.
📊
Key Findings & Data:Methods: We enrolled 104 patients, including 52 men and 52 women who visited our hospital and had anti-hepatitis C virus (HCV) positivity.
💡
Conclusion & Impact:Conclusion: In our study, the prevalence of MS was significantly higher in female patients with HCV antibodies than in male patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Research has shown that hepatitis C infection, metabolic syndrome (MS), and non-alcoholic fatty liver syndrome are associated. This study was designed to assess the parameters of MS in people with hepatitis C antibodies. Methods: We enrolled 104 patients, including 52 men and 52 women who visited our hospital and had anti-hepatitis C virus (HCV) positivity. In the patient group, different examinations were performed as per the MS criteria in the Adult Treatment Panel (ATP) III and International Diabetes Federation (IDF) guidelines. Results: As per the ATP III criteria, the prevalence of MS was 36.5% (n=38) in the total population, 55.8% (n=29) in women, and 17.3% (n=9) in men in our study. When the IDF criteria were applied, the MS prevalence was 48.1% (n=50) in the total population, 65.4% (n=34) in women, and 30.8% (n=16) in men. Conclusion: In our study, the prevalence of MS was significantly higher in female patients with HCV antibodies than in male patients.

🔖

Cite This Article

ŞENOĞLU, S., IŞIK, A. C., KORKUSUZ, R., ATAOĞLU, H. E., IŞIK, M. E., ÖZGÜMÜŞ, S. (2022). Incidence of Metabolic Syndrome in Anti-Hepatitis C Virus Positive Patients. Southern Clinics of Istanbul Eurasia, Cilt: 31 - Sayı: 4, 370–375. https://ajindex.com/articles/592771

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Thomas DL, Ray SC, Lemon SM. Hepatitis C. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th Ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 1950−81
  2. Türkiye Endokrinoloji ve Metabolizma Derneği Metabolik Sendrom Çalışma Grubu. Metabolik Sendrom Kılavuzu 2009. Available at: http://temd.org.tr/admin/uploads/tbl_yayinlar/metabolik_sendrom. pdf. Accessed Dec 10, 2020
  3. Cheng YL, Wang YC, Lan KH, Huo TI, Huang YH, Su CW, et al. Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Ann Hepatol 2015;14:181−9
  4. Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med 2015;5:7−13
  5. Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthi S, De Silva AP, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 2009;24:1284−8
  6. Scorletti E, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 2011;40:332−43
  7. Berk PD. Introduction. Hepatitis C: The virus that created hepatology. Semin Liver Dis 2000;20:i-ii
  8. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210−4
  9. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556−62
  10. Kozan Ö, Oğuz A, Abacı A, Erol C, Öngen Z, Temizhan A, et al. Türkiye Metabaolik Sendrom Prevalans Çalışması (METSAR) Sonuçları. II. Metabolik Sendrom Sempozyumu. İstanbul Mart 2005
  11. Merle P, Trepo C. Treatment of extrahepatic diseases caused by hepatitis B and hepatitis C Viruses. In: Thomas H, Lemon S, Zuckerman A, editors. Viral Hepatitis. 3rd ed. New Jersey: Blackwell Publishing; 2005. p. 780−93
  12. Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol 2016;22:1461−76
  13. Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 2012;56:S56− S65
  14. Hsu CS, Liu CH, Liu CJ, Hsu SJ, Chen C